All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2016-11-15T10:07:21.000Z

CLL patients with del17p: in an extended phase I trial with a p53 inhibitor, APR-246 shows encouraging results

Nov 15, 2016
Share:

Bookmark this article

TP53 mutations are common in hematological malignancies and confer a dismal prognosis. APR-246 is the first compound targeting mutant p53 to enter into a clinical trial.

In this first in-man study, APR-246 was given daily as a 2h intravenous infusion for 4 consecutive days with a maximum tolerated dose of 60mg/kg daily. This trial was an extension of the first in-man study to determine the dose limiting toxicity (DLT), safety, pharmacokinetic profile, and anti-tumor effects of APR-246. The data was published by S. Deneberg, et al., in Blood Cancer Journal in July 2016. The trial was conducted in accordance to the Declaration of Helsinki and ICH-GCP guidelines and was registered at ClinicalTrial.gov (NCT00900614).

The key findings were:

  • Two patients with Chronic Lymphocytic Leukemia (CLL) with a deletion of 17p, not eligible for other therapies, were included in this trial
  • One CLL patient (01-101), receiving a total infusion of 135mg/kg, showed a >25% reduction in lymphocyte count and a >25% reduction in lymph node size between day 1 and day 4. This patient received two additional treatment cycles at the 105 mg/kg dose, but no further responses were seen and the patient progressed during cycle 2

The take home messages are as follows:

  • APR-246 when administered to CLL patients with TP53 mutations, at a dose of 67.5mg/kg given as a 6h infusion on 4 consecutive days, was considered safe, well tolerated and showed some signs of clinical activity. However, sample size needs to be increased
  • The preliminary data shown by this trial lays the groundwork for exploring the potential of APR-246 in other hematological indications, preferentially in combination with standard chemotherapy

The full article can be found here.

  1. Deneberg S, et al. An open-label phase I dose-finding study of APR-246 in hematological malignancies. Blood Cancer J. 2016 Jul 15;6(7):e447. doi: 10.1038/bcj.2016.60.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox